Strongbridge Biopharma plc to Host Third Quarter 2020 Financial Results Conference Call on October 29, 2020
Strongbridge Biopharma (Nasdaq: SBBP) has announced a conference call scheduled for October 29 at 4:30 p.m. ET to discuss its third quarter 2020 financial results and provide a business update. This call will follow the anticipated release of financial results that same day. The call can be accessed via phone or through an audio webcast on the company’s website. Strongbridge focuses on therapies for rare diseases, including RECORLEV® for Cushing’s syndrome and KEVEYIS® for primary periodic paralysis, both with orphan drug designations.
- Strongbridge's pipeline includes RECORLEV® and veldoreotide, targeting rare diseases with unmet needs.
- Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and European Medicines Agency.
- None.
DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Thursday, October 29 at 4:30 p.m. ET to discuss the Company’s third quarter 2020 financial results and to provide a business update. The conference call will follow the anticipated release of the Company’s financial results earlier that day.
Event Details
Strongbridge will host a conference call on Thursday, October 29 at 4:30 p.m. ET. To access the live call, dial 844-285-7153 (domestic) or 478-219-0180 (international) with conference ID 1287444. The conference call will also be audio webcast from the Company’s website at www.strongbridgebio.com under the “Investor/Webcasts and Presentations” section. A replay of the call will be made available for one week following the conference call. To hear a replay of the call, dial 855-859-2056 (domestic) or 404-537-3406 (international) with conference ID 1287444.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com
FAQ
What is the date and time of Strongbridge Biopharma's conference call?
What will be discussed during the conference call?
How can I access the Strongbridge conference call?
What are the main products in Strongbridge Biopharma's pipeline?
What designations have Strongbridge's drugs received?
